Oslo - Delayed Quote NOK

Hofseth BioCare ASA (HBCO.OL)

Compare

3.1700

0.0000

(0.00%)

At close: January 28 at 10:49:23 AM GMT+1

Hofseth Biocare ASA: Commences the project for a second hydrolysis plant in Norway to triple capacity

Hofseth BioCare ASA ("HBC" or the "Company", and together with its consolidated subsidiaries, the "Group") is pleased to announce a Board resolution to start a project to build a second hydrolysis plant in Berkåk, Norway through HBC Berkåk AS ("HBC Berkåk"), a wholly owned subsidiary of the Company. HBC Berkåk will be engaged within the manufacturing, marketing and sale of clinically proven, human grade, sustainable marine proteins, collagens, and oils from Norwegian Atlantic salmon harvested fr

GlobeNewswire last month

HOFBF
Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT

HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating loss (EBITDA) for the quarter was NOK -21.0m (-16.2m) and NOK -39.2m (-26.3m) for the first nine months. Operating result (EBIT) amounted to NOK -30.5m (-25.2m) in the third quarter 2024. Cash and cash equivalents decreased by NOK 1.9m during the quarter, leaving a total holding at NOK 23.4m at the end of September, compared to NOK 25.3m at the end of the sec

GlobeNewswire 2 months ago

HOFBF
Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT

Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral formulation in combination with standard of care hormonal-targeting therapy. Oral FT-002a significantly augmented the anti-tumour activity of enzalutamide (Xtandi®) the market-leading androgen receptor inhibitor, in models of indolent and aggressive prostate cancers. Prostate cancer remains the mos

GlobeNewswire 3 months ago

HOFBF
Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT

HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year. Adjusted for the sale of assets in the second quarter, sales revenues were NOK 72.2m (50.7m) for the quarter, representing an increase compared to the same quarter in 2023 of 42 percent. Cash and cash equivalents increased by NOK 3.1m during the quarter, leaving total holding at NOK 25.3m at the end of June, compared to NOK 22.4m at the end of March. Including credit facilities,

GlobeNewswire 5 months ago

HOFBF
Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY

Ålesund, Norway, 14 August, 2024 - Hofseth BioCare (HBC), a leader in science-led marine nutrition, proudly announces compelling new findings from a recent study on the benefits of its enzymatically liberated salmon oil, OmeGo®, for COVID-19 recovery. Published in the International Journal of Molecular Sciences, this pioneering research demonstrates that OmeGo® has the potential to improve immune responses and reduce inflammation in individuals with mild to moderate COVID-19 infection, caused by

GlobeNewswire 5 months ago

HOFBF
Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.

Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate MA-022a to its majority-owned subsidiary HBC Immunology Inc. ("HBCI"). The patent underlying the project has been valued by KWC AS at $4.5m (based on relief-from royalty method) and HBC will therefore receive 956,813 common shares in HBCI for the transfer of the patent to HBCI. HBC has booked approx

GlobeNewswire 6 months ago

HOFBF
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an additional distributor in China. Shanghai-based Lithy has entered into an agreement with HBC to distribute its science-led marine nutrition ingredients, ProGo® bioactive peptides, OmeGo® full spectrum omegas and CalGo® natural, undenatured type II collagen, to supplement manufacturers across the country. Lithy, which was established in 2002, has three subsidiaries that su

GlobeNewswire 7 months ago

HOFBF
Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT

The first quarter of 2024 continued on the positive trend for HBC. Sales revenues came in at NOK 52m vs NOK 44m last year, a growth of 17 % YoY. The underlying growth we are seeing is coming from both the ingredients business and finished products channels. The ingredients business continues to have solid demand growth especially for our core petfood products, and we have seen increased demand for our premium pure SPH product within this segment. We are also excited to have launched two new prod

GlobeNewswire 8 months ago

HOFBF
Hofseth Biocare ASA: Annual General Meeting completed

Hofseth BioCare ASA held its Annual General Meeting on 10 May 2024. 270,174,810 shares, amounting to 68.38 per cent of the share capital, were represent in the meeting or by proxy. All proposals were resolved as presented in the notice issued on 19 April 2024 and the recommendations from the Election committee. The minutes from the Annual General Meeting are attached. For further information, please contact: Jon Olav Ødegård, CEO at HBC Phone: +47 936 32 966 E-mail: joo@hofsethbiocare.no About H

GlobeNewswire 8 months ago

HOFBF
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024

The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 10 May 2024 at 13:00 CET. The notice of the Annual General Meeting is attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: investor@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug l

GlobeNewswire 9 months ago

HOFBF
Hofseth Biocare ASA: HBC ANNUAL REPORT 2023

The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2023 and the Company has today published the Annual Report and Sustainability Report for 2023. Please find the Annual Report and ESG Report attached. For further information, please contact:Christel Elise Kanli, CFO of Hofseth BioCare ASAPhone: +47 41623188E-mail: ck@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pha

GlobeNewswire 9 months ago

HOFBF
Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION

Please find the HBC Company Presentation attached. For further information, please contact: James Berger, Chief Commercial Officer of Hofseth BioCare ASA Phone: +41 79 950 10 34 E-mail: jb@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug leads. Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical stu

GlobeNewswire 10 months ago

HOFBF
Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN

Kristin Fjellby Grung, Chair of the Board of Hofseth BioCare ASA, has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in the District Court of Møre and Romsdal and will therefore not be able to continue to serve in the position as Chair of the Board. Grung has been a member of the Board of Directors since December 2020, and assumed the position as Chair in April 2022. The Board would like to thank Grung for her servi

GlobeNewswire 10 months ago

HOFBF
Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT

HBC had gross operating revenues of NOK 47.4m (33.6m) in the fourth quarter and NOK 218.5m (120.4m) for the full year. Adjusted for the sale of assets in the second quarter, operating revenues were NOK 194.9m for the full year, representing an increase compared to 2022 of 38 percent. Cash and cash equivalents increased by NOK 6.2m during the quarter, leaving total holding at NOK 23.9m at the end of the year, compared to NOK 32.4m at the end of 2022. Including credit facilities, HBC had NOK 62.5m

GlobeNewswire 11 months ago

HOFBF
Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity

HBC Immunology Inc. (70.6% owned by Hofseth BioCare ASA) reports today the successful completion of the first in vivo study within its prostate cancer development program. The study assessed whether the combination of targeted hormonal therapy, bicalutamide, and FT-002 or FT-005 was better at suppressing PC3 tumour growth compared to control (no treatment). PC3 represents a model of very aggressive prostate cancer which is resistant to standard treatment. The FT peptides are HBCI’s two leading d

GlobeNewswire 11 months ago

HOFBF

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hofseth BioCare ASA (HBCO.OL)

Hofseth Biocare ASA: Commences the project for a second hydrolysis plant in Norway to triple capacity

Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT

Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT

Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT

Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY

Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT

Hofseth Biocare ASA: Annual General Meeting completed

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024

Hofseth Biocare ASA: HBC ANNUAL REPORT 2023

Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION

Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN

Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT

Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity